FORM 4 [X] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

MCDADE MARK		 2. Issuer Name and Ticker or Trading Symbol

Aimmune Therapeutics, Inc. [ AIMT ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director                    _____ 10% Owner
_____ Officer (give title below)    _____ Other (specify below)
(Last)          (First)          (Middle)

C/O AIMMUNE THERAPEUTICS, INC., 8000 MARINA BOULEVARD, SUITE 300		 3. Date of Earliest Transaction (MM/DD/YYYY)

10/10/2020
(Street)

BRISBANE, CA 94005-1884
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
 6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock, $0.0001 par value 10/10/2020  U  26852 D$34.50 0 D  
Common Stock, $0.0001 par value 10/13/2020  D  7840 (1)(2)D$34.50 0 D  

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)		2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)		8. Price of Derivative Security
(Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy) $3.02 10/13/2020  D     104842   (3) (3)Common Stock 104842 $31.48 0 D  
Stock Option (right to buy) $15.40 10/13/2020  D     19755   (3) (3)Common Stock 19755 $19.10 0 D  
Stock Option (right to buy) $18.26 10/13/2020  D     17500   (3) (3)Common Stock 17500 $16.24 0 D  
Stock Option (right to buy) $32.79 10/13/2020  D     7500   (3) (3)Common Stock 7500 $1.71 0 D  
Stock Option (right to buy) $19.90 10/13/2020  D     11432   (3) (3)Common Stock 11432 $14.60 0 D  
Stock Option (right to buy) $17.11 10/13/2020  D     15398   (3) (3)Common Stock 15398 $17.39 0 D  
Explanation of Responses:
(1) Disposed of to SPN MergerSub, Inc. ("Merger Sub"), which, pursuant to the Agreement and Plan of Merger, dated August 29, 2020, by and between the Issuer, Societes des Produits Nestle S.A., ("Nestle"), and Merger Sub (the "Merger Agreement"), commenced a tender offer to acquire any and all of the outstanding shares of the Issuer's common stock (other than those shares owned by Nestle and its affiliates) at a purchase price of $34.50 per share (the "Offer Price").
(2) Pursuant to the Merger Agreement, each Issuer restricted stock unit ("RSU") that was outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") vested in full, terminated, and was converted into the right to receive a cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of common stock subject to the RSU.
(3) Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option.
Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
MCDADE MARK
C/O AIMMUNE THERAPEUTICS, INC.
8000 MARINA BOULEVARD, SUITE 300
BRISBANE, CA 94005-1884		X
Signatures
/s/ Douglas T. Sheehy, as Attorney-in-Fact for Mark D. McDade10/14/2020
**Signature of Reporting PersonDate
Aimmune Therapeutics (NASDAQ:AIMT)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Aimmune Therapeutics Charts.
Aimmune Therapeutics (NASDAQ:AIMT)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Aimmune Therapeutics Charts.